Lideur mondiale dans étude de LLLT:
Michael R Hamblin Ph.D.
Associate Professor
Department of Dermatology
Harvard Medical School
BAR 414
Wellman Center for Photomedicine
Massachusetts General Hospital
40 Blossom Street
Boston MA 02114
USA
Member of Affiliated Faculty of Harvard-MIT Division of Health Sciences and
Technology
Tel 617-726-6182
Fax 617-726-6643
e-mail hamblin@helix.mgh.harvard.edu
“Low level laser (light) therapy (LLLT) also known as photobiomodulation (PBM) therapy has been practiced for almost fifty years, and hundreds of positive clinical trials and thousands of laboratory studies have been published. Despite these impressive accomplishments LLLT has still not reached the stage of acceptance by mainstream medicine. The reasons for this were discussed at a recent Optical Society of America (OSA) Incubator meeting in Washington DC in 2014. Uncertainty about mechanisms was highlighted, and this paper will describe the current thinking. To drive LLLT towards mainstream medicine, we need better guidelines with standardized protocols and consistent parameters. Studies should be published in higher impact scientific and medical journals. Companies should avoid false promises and deceptive marketing, and physicians should receive a clearly defined return on investment with insurance reimbursement.”
Source:
Anglais:
http://photobiology.info/Hamblin.html
Russe:
https://flyclipart.com/ru-hamblin
He adviced me to use this model: